EUVIMEDEUVIMED entdecken
Übersichtsarbeit

NRF2 as a ferroptosis gatekeeper in colorectal cancer: implications for therapy

Amr Ali Mohamed Abdelgawwad El-Sehrawy iD, Abdulla A Al-Dulaimi, Ali G Alkhathami, Renuka Jyothi S, Rajashree Panigrahi iD, Amrita Pargaien, Udaybir Singh, Ahmed Husseini, Mohammed Jawad Alnajar

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025-12 · 398 (12) · 16479-16506

DOI: 10.1007/s00210-025-04324-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 03.07.2025. Verfasst von Amr Ali Mohamed Abdelgawwad El-Sehrawy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Mansoura University, Mansoura, Egypt. sehrawyamr@gmail.com. Hauptthemen laut MEDLINE: Ferroptosis, NF-E2-Related Factor 2, Colorectal Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 196 Literaturangaben. Gefördert von: King Khalid University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is one of the primary cancer concerns for global health, with high incidence and mortality rates worldwide. The natural history of CRC is a complicated and multistep process characterized by genetic alterations with various biological features, including genomic instability, excessive cell proliferation, angiogenesis, and metastasis. This review focuses on the delicate interaction between ferroptosis, a recently unveiled form of iron-dependent cell death, the nuclear factor erythroid 2-related factor 2 (NRF2), an important transcriptional factor that controls the pharmacology of oxidative stress and cellular metabolism in the context of CRC. NRF2 is critical for regulating the cells' antioxidant response to compensate for the damage caused by reactive oxygen species and maintain iron homeostasis. By this, NRF2 would function as a negative regulator of ferroptosis, which could be an undesirable process for tumour cells if induced. Certainly, NRF2 activities lower the levels of ROS and manipulate the labile iron pool (LIP). The relationship between NRF2 and ferroptosis is further complicated by the actions of a downstream gene, HO-1, whose expression is regulated by NRF2. NRF2 promotes the transcription of glutathione peroxidase 4 (GPX4) and SLC7A11 (a component of the cystine/glutamate antiporter system Xc⁻). It also regulates iron metabolism by upregulating genes such as ferritin heavy chain (FTH1) and ferroportin (FPN), thus further suppressing ferroptosis. Mounting evidence suggests that targeting the NRF2-ferroptosis axis by Tagitinin C, Lysionotin, Ginsenoside Rh3, Cetuximab, Esculin, Brassinin, and Angelic acid could open up novel therapeutic avenues for treating colorectal cancer, thereby improving CRC patient outcomes and overall survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisNF-E2-Related Factor 2Colorectal NeoplasmsHumansAnimalsAntineoplastic AgentsIronReactive Oxygen Species

Stichwörter der Autor:innen

CRCCell deathFerroptosisHO-1NRF2

Substanzen

NF-E2-Related Factor 2NFE2L2 protein, humanAntineoplastic AgentsIronReactive Oxygen Species

Autor:innen und Institutionen

  • Department of Internal Medicine, Mansoura University, Mansoura, Egypt. sehrawyamr@gmail.com.
  • College of Nursing, University of Al Maarif, Al Anbar, 31001, Iraq. Abdulla.A.dulaimi1988@gmail.com.
  • Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
  • Department of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to Be University), Bangalore, Karnataka, India.
  • Department of Microbiology, IMS and SUM Hospital, Siksha 'O' Anusandhan (Deemed to Be University), Bhubaneswar, Odisha, 751003, India.
  • Department of Pharmacy, Graphic Era Hill University, Bhimtal, India.

ORCID-Profile: Amr Ali Mohamed Abdelgawwad El-Sehrawy, Rajashree Panigrahi

Förderung

  • King Khalid University

Zitieren

APA

Abdelgawwad El-Sehrawy, A. A. M., Al-Dulaimi, A. A., Alkhathami, A. G., S, R. J., Panigrahi, R., Pargaien, A., Singh, U., Husseini, A., & Alnajar, M. J. (2025). NRF2 as a ferroptosis gatekeeper in colorectal cancer: implications for therapy. Naunyn-Schmiedeberg's Archives of Pharmacology, 398(12), 16479-16506. https://doi.org/10.1007/s00210-025-04324-3

Vancouver

Abdelgawwad El-Sehrawy AAM, Al-Dulaimi AA, Alkhathami AG, S RJ, Panigrahi R, Pargaien A, et al. NRF2 as a ferroptosis gatekeeper in colorectal cancer: implications for therapy. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025;398(12):16479-16506. doi:10.1007/s00210-025-04324-3

BibTeX
@article{AbdelgawwadElSehrawy2025,
  author = {Abdelgawwad El-Sehrawy, Amr Ali Mohamed and Al-Dulaimi, Abdulla A and Alkhathami, Ali G and S, Renuka Jyothi and Panigrahi, Rajashree and Pargaien, Amrita and Singh, Udaybir and Husseini, Ahmed and Alnajar, Mohammed Jawad},
  title = {NRF2 as a ferroptosis gatekeeper in colorectal cancer: implications for therapy},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  volume = {398},
  number = {12},
  pages = {16479--16506},
  doi = {10.1007/s00210-025-04324-3}
}
Kostenlos starten →